



Cardiopulmonary Imaging Utilization and Findings among Hospitalized COVID-19 Patients in Latin America

ORIGINAL RESEARCH

(From “RIMAC: Registry IMAGING Cardiopulmonary among Hospitalized COVID-19 Patients in LATAM”)

Journal of Global Health

SALVADOR V. SPINA

BEATRIZ DOMÍNGUEZ

MARCELO L. CAMPOS VIEIRA

FEDERICO CAMPOS

CÉSAR J. HERRERA

SERGIO M. ALDAY RAMIREZ

ANA G. MÚNERA ECHEVERRI

ANGELA V. CACHICATARI BELTRAN

PAMELA ROJO

DANIELA ALVAREZ

ALMA S. ARRIOJA SALAZAR

PATRICIA DE OLIVEIRA ROVERI

ZUILMA Y. VÁZQUEZ ORTIZ

CARLOS ROSALES IXCAMPARIJ

ROBERTO BALTODANO ARELLANO

ENDLER OTONIEL GONZÁLEZ

GRACIELA REYES

PEDRO VARGAS

ROCÍO ACEVES MILLÁN

MAXIMILIANO FLORES FLAMAND

JUAN A. CALDERÓN GONZÁLEZ

ROSA L. LÓPEZ MARTÍNEZ

ANA C. CAMARAZANO

LUCIANA MEZA

EDGAR AVILÉS

SAMIRA SAADY MORTHY

MARCO A. CABRERA

RUDY OVALLE

MARÍA F. GRANDE RATTI

STALIN MARTÍNEZ

JORGE LOWENSTEIN

OSCAR A. PÉREZ ORPINEL

RODRIGO HERNÁNDEZ VYHMEISTER

MAURICIO POTITO

PAMELA PIÑA SANTANA

MARÍA VERÓNICA ESPINOZA ARREGUI

JAIME A. IBARRA BURGOS

JORGE MARTE BAEZ

ALEJANDRA RIVERA

CONSUELO ORIHUELA SANDOVAL

BEATRIZ A. FERNÁNDEZ CAMPOS

MARCOS GRANILLO FERNÁNDEZ

KELLY M. CUPE CHACALCAJE

ROHIT LOOMBA

MARIELA DE SANTOS

SAÚL FLORES

TANIA R. AFONSO

JOSÉ M. HERNÁNDEZ

TOMÁS MIRANDA AQUINO

RICARDO PIGNATELLI

ANA L. LALYRE ACOSTA

CORRESPONDING AUTHOR:

Salvador Vicente Spina, MD

Medical Director of Echocardiography, Associate Chief, Cardiology, Hospital Aeronáutico Central, Buenos Aires City, Viamonte 251, Ramos Mejía, Provincia Bs As. CP: 1704, AR

salvadorvspina@gmail.com

KEYWORDS:

Cardiopulmonary Images; SARS-CoV-2; COVID-19; LATAM; RIMAC

TO CITE THIS ARTICLE:

Spina SV, Campos Vieira ML, Herrera CJ, Múnera Echeverri AG, Rojo P, Arrijoja Salazar AS, Vázquez Ortiz ZY, Arellano RB, Reyes G, Millán RA, Calderón González JA, Camarozano AC, Avilés E, Cabrera MA, Grande Ratti MF, Lowenstein J, Vyhmeister RH, Santana PP, Ibarra Burgos JA, Rivera A, Fernández Campos BA, Cupe Chacalcaje KM, De Santos M, Afonso TR, Aquino TM, Lalyre Acosta AL, Domínguez B, Campos F, Alday Ramirez SM, Cachicatari Beltran AV, Alvarez D, de Oliveira Roveri P, Ixcamparij CR, González EO, Vargas P, Flamand MF, López Martínez RL, Meza L, Morthy SS, Ovalle R, Martínez S, Pérez Orpinel OA, Potito M, Espinoza Arregui MV, Baez JM, Sandoval CO, Fernández MG, Loomba R, Flores S, Hernández JM, Pignatelli R. Cardiopulmonary Imaging Utilization and Findings among Hospitalized COVID-19 Patients in Latin America. *Global Heart*. 2022; 17(1): 49. DOI: <https://doi.org/10.5334/gh.1134>

ABSTRACT

Objectives: Describe the use and findings of cardiopulmonary imaging—chest X-ray (cX-ray), echocardiography (cEcho), chest CT (cCT), lung ultrasound (LUS), and/or cardiac magnetic resonance imaging (cMRI)—in COVID-19 hospitalizations in Latin America (LATAM).

Background: There is a lack of information on the images used and their findings during the SARS-CoV-2 pandemic in LATAM.

Methods: Multicenter, prospective, observational study of COVID-19 inpatients, conducted from March to December 2020, from 12 high-complexity centers, in nine LATAM countries. Adults (>18 years) with at least one imaging modality performed, followed from admission until discharge and/or in-hospital death, were included.

Results: We studied 1,435 hospitalized patients (64% males) with a median age of 58 years classified into three regions: Mexico (Mx), 262; Central America and Caribbean (CAC), 428; and South America (SAm), 745. More frequent comorbidities were overweight/obesity, hypertension, and diabetes. During hospitalization, 58% were admitted to the ICU. The in-hospital mortality was 28%, and it was highest in Mx (37%).

The most frequent images performed were cCT (61%), mostly in Mx and SAm, and cX-ray (46%), significant in CAC. The cEcho was carried out in 18%, similarly among regions, and LUS was carried out in 7%, with a higher frequency in Mx. Abnormal findings on the cX-ray were peripheral or basal infiltrates, and in cCT abnormal findings were the ground glass infiltrates, more commonly in Mx. In LUS, interstitial syndrome was the most abnormal finding, predominantly in Mx and CAC.

Renal failure was the most prevalent complication (20%), predominant in Mx and SAm. Heart failure developed in 13%, predominant in Mx and CAC. Lung thromboembolism was higher in Mx while myocardial infarction was in CAC.

Logistic regression showed associations of abnormal imaging findings and their severity, with comorbidities, complications, and evolution.

Conclusions: The use and findings of cardiopulmonary imaging in LATAM varied between regions and had a great impact on diagnosis and prognosis.

INTRODUCTION

BACKGROUND/RATIONALE

The COVID-19 pandemic is one of the largest and most active threats to health care in living memory. As the impact of the virus continues, systems of care around the world have responded with unprecedented protective measures.

SARS-CoV-2 predominantly affects adults, and disease severity increases with age and number of comorbidities. COVID-19 infection is mainly characterized by upper airway inflammation, which can progress into interstitial pneumonia and eventually to acute respiratory distress syndrome (ARDS) in the most severe cases. Cardiovascular complications such as thromboembolic phenomena, acute coronary syndrome, heart failure, and renal dysfunction are known to occur [1–4].

Cardiopulmonary imaging plays an essential role in the diagnosis of SARS-CoV-2 infection and its complications. Imaging can assess the extent of disease, prognosis, and evaluation of therapeutic interventions [1–7]. Imaging services resources (ISR) such as electrocardiogram (ECG) [8, 9], chest X-ray (cX-ray) [10], echocardiogram (cEcho) [11–14], lung ultrasound (LUS) [15, 16], and chest computed tomography (cCT) [17, 18] have been at the front line of the pandemic. Each technique offers well-known advantages, however despite the high number of cases of infection and deaths from COVID-19, their specific application and utilization in low- and middle-income countries remains unknown.

Preventive distancing and biosecurity measures during testing can protect patients and staff, thus abbreviated evaluations and imaging interventions have become the norm.

The main objectives were as follows:

1. To describe the use and findings of cardiopulmonary imaging modalities performed for the diagnosis and treatment of patients hospitalized for SARS-CoV-2 infection in Latin America (LATAM)
2. To compare the differences between three geographic regions of LATAM countries: Mexico (Mx), Central America and Caribbean (CAC), and South America (SAm)

We also describe their demographic parameters, comorbidities, in-hospital events (or clinical complications), laboratory results, and concomitant treatments of all included patients.

METHODS

STUDY DESIGN AND SETTING

We conducted a multicenter, prospective, observational study based on the RIMAC registry that included adult patients with SARS-CoV-2 disease admitted from March to December 2020, in 12 high-complexity centers (level III or IV) from nine countries—Argentina, Brazil, Colombia, Chile, Guatemala, Mexico, Panama, Perú, and the Dominican Republic—which were divided into three geographic regions. All the centers had availability of the total imaging modalities analyzed. The total number of referral beds in each center was greater than 185, which doubled and tripled according to the needs of each region. We used STROBE for observational studies as a reporting guideline.

PARTICIPANTS

The cohort included a consecutive sample of patients, followed up from admission until discharge and/or in-hospital death. Inclusion criteria were patients >18 years old, positive COVID-19 CRP and/or COVID-19 positive IgM and IgG antibodies, hospitalized status, and at least one imaging modality performed according to each treating physician's criteria (cX-ray, cEcho, LUS, cCT, or cMRI).

The exclusion criteria were patients <18 years old, lack of complete documentation on COVID-19 infection, nonhospitalized patients, failure to perform an imaging modality, or inadequate quality for diagnosis and/or treatment (cX-ray, cEcho, LUS, cCT, or cMRI).

DATA SOURCE PROCEEDING/VARIABLES

The baseline data (demographic, epidemiological, clinical, imaging, laboratory, treatment, and outcome) was reviewed and collected by the research team, came from the medical records of the patients, using a standardized unique form (RIMAC Registry) in all centers, and was securely stored in a database created for this purpose for subsequent analysis. Each patient was assigned a de-identifying code. Local IRB approval from each center was obtained, and researchers were not involved in direct care of the subjects. Informed consent was not obtained in all centers because it was an observational, noninterventional study of registry research with minimal risk. Most patients were aware that their data was going to be used for research purposes through verbal explanations.

Patients were prospectively monitored for major complications during hospitalization.

STATISTICAL ANALYSES

All statistical analyses were conducted using STATA, version 17.0. Descriptive variables were summarized using proportions for categorical variables, and mean (\pm standard deviation) or median (interquartile range) as appropriate.

We divided the cohort into three geographic regions for multiple comparisons. These were identified and agreed upon by the authors a priori: Mexico (Mx) as a representation of the Latin population of North America; Central America, and Caribbean (CAC), which included Guatemala, Panamá, and the Dominican Republic; and South America (SAm), which included Argentina, Brazil, Chile, Colombia, and Perú.

Comparisons between regions were performed using Pearson's 2 test with Bonferroni's correction for categorical variables. Meanwhile, for continuous variables we used analysis of variance (ANOVA) or Kruskal-Wallis H test to compare differences among groups. In these cases of multiple comparison, a p-value of ≤ 0.016 was considered strength of evidence.

In addition, univariate and multivariate logistic regressions were performed to explore factors associated with a specific clinical imaging modality. The modality of choice was based on the treating physician, the clinical presentation, the availability of diagnostic images, and local guidelines in place for imaging. We have selected clinical variables as potential confounders of adjustment. The adjusted analysis was based on the comparison from different regions: Mx, CAC, and SAM were defined as the exposure variable. The strength of evidence level was set at 0.05 (two-tailed), and odds ratios (OR) and their respective 95% confidence intervals (95%CI) were reported.

RESULTS

PARTICIPANTS/DESCRIPTIVE DATA

There were 1,549 hospitalized patients recorded in the RIMAC registry, and 114 patients were excluded due to a lack of complete documentation on COVID-19 infection. The remaining 1,435 patients were included in the study (64% males) with a median age of 58 (SD 16.6); their geographical distribution was 262 from Mx, 428 from CAC, and 745 from SAM (Figure 1).



Figure 1 RIMAC Registry. Participating regions, countries and institutions (1,435 patients).

A total of 708 patients (49%) were admitted to the ward, and 727 (51%) patients were initially admitted to the ICU. We found strong evidence that patients were more frequently admitted in wards in Mx in comparison with the other regions. The ICU patients subsequently increased to 836 (58%) during total hospital stay (most of them were Mexican patients) and thus normalized the differences among regions. The median number of hospitalization days was 17 (SD 17.2), and the median ICU days was 13 (SD 14.2). This was significantly lower in CAC.

The most common comorbidities were overweight/obesity (61%), hypertension (45%), and diabetes (27%). There were differences across regions: body mass index (BMI) was registered in 1,180 patients, and overweight/obesity (BMI ≥ 25) was significantly more prevalent in

Mexico (42%) especially due to obesity (BMI ≥ 30). Hypertension (HBP) was significantly higher in CAC (60%), and diabetes (DBT) predominated in Mx and CAC (34%). Ischemic heart disease, chronic obstructive pulmonary disease (COPD), renal failure, and myocardopathy were below 7% of the population (Table 1).

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Demographic Variables					
Age (years)	57.95 (SD 16.62)	55.56 (SD 15.41)	59.86 (SD 16.91)	57.69 (SD 16.77)	0.002 0.003 0.094 0.222
Male gender	64.46% (925)	58.40% (153)	70.33% (301)	63.22% (471)	0.004 0.001 0.014 0.166
Baseline Comorbidities					
Overweight/obesity (BMI ≥ 25)	61.25% (879)	80.92% (212)	64.95% (278)	52.21% (389)	0.001 0.001 0.001 0.001
Overweight (BMI 25–29)	35.75% (513)	38.55% (101)	43.93% (188)	30.07% (224)	0.001 0.165 0.001 0.012
Obesity(BMI ≥ 30)	25.51% (366)	42.37% (111)	21.03% (90)	22.15% (165)	0.001 0.001 0.654 0.001
HBP	45.37% (651)	36.26% (95)	60.28% (258)	40.00% (298)	0.001 0.001 0.001 0.286
DBT	26.83% (385)	34.35% (90)	33.64% (144)	20.27% (151)	0.001 0.849 0.001 0.001
Former tobacco use	14.15% (203)	6.87% (18)	19.63% (84)	13.56% (101)	0.001 0.001 0.006 0.004
Active tobacco use	8.43% (121)	13.74% (36)	7.94% (34)	6.85% (51)	0.002 0.014 0.485 0.001
Ischemic heart disease	6.76% (97)	4.96% (13)	9.58% (41)	5.77% (43)	0.019 0.028 0.015 0.623
COPD	6.62% (95)	2.67% (7)	2.10% (9)	10.60% (79)	0.001 0.630 0.001 0.001

Table 1 Demographic variables and baseline comorbidities.

Notes: * Each cell contains four p-values. The first p-value corresponds to chi-squared test (for categorical variables) or one-way ANOVA test (for numerical variables). Only a $p \leq 0.016$ was considered statistically significance.

The second, third, and fourth p-values correspond to multiple comparisons between groups: Mx and CAC, CAC and SAM, and SAM and Mx, respectively. We used multiple chi-squared tests and ANOVA with Bonferroni correction.

HBP: high blood pressure; DBT: diabetes; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus.

(Contd.)

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Renal failure	4.32% (62)	1.91% (5)	2.80% (12)	6.04% (45)	0.003 0.462 0.013 0.008
Myocardial pathology	4.74% (68)	0.00% (0)	9.11% (39)	3.89% (29)	0.001 0.001 0.001 0.001
Valvular heart disease	1.74% (25)	2.29% (6)	2.57% (11)	1.07% (8)	0.128 N/A
HIV	0.42% (6)	0.38% (1)	0.00% (0)	0.67% (5)	0.229 N/A

MAIN RESULTS

Cardiopulmonary imaging utilization

The most common cardiopulmonary imaging performed in our cohort were cCT (61%) and cX-ray (46%); cEcho was carried out in 18% of patients, and LUS was carried out in 7% of patients. The use of imaging modalities was different across regions: cCT was more frequent in Mx and SAm, and cX-ray was significantly more common in CAC. cEcho was almost the same among regions with a small predominance in Mx. LUS was significantly more common in Mx. Brazil had the highest use of both modalities if we analyze based on country. ECG use was limited (24%) due to the biosafety measures implemented during COVID-19. The lowest use was in SAm (except Brazil) (Table 2). cMRI was performed in only one patient in the cohort and was not taken into account for the statistical analysis.

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Chest computed tomography (cCT)	61.53% (883)	69.08% (181)	32.24% (138)	75.70% (564)	0.001 0.001 0.001 0.036
Chest X-ray (cX-ray)	45.99% (660)	38.55% (101)	91.12% (390)	22.68% (169)	0.001 0.001 0.001 0.001
Echocardiogram (cEcho)	18.54% (266)	24.43% (64)	18.93% (81)	16.24% (121)	0.013 0.085 0.241 0.003
Lung ultrasound (LUS)	7.25% (104)	22.14% (58)	0.23% (1)	6.04% (45)	0.001 0.001 0.001 0.001
Electrocardiogram (ECG)	24.32% (349)	41.22% (108)	37.62% (161)	10.74% (80)	0.001 0.346 0.001 0.001

Table 2 Image modalities used.

Notes: * Each cell contains four p-values.

The first p-value corresponds to chi-squared test (for categorical variables) or one-way ANOVA test (for numerical variables). Only a $p \leq 0.016$ was considered statistically significance.

The second, third, and fourth corresponds to multiple comparisons between groups: Mx and CAC, CAC and SAm, and SAm and Mx, respectively. We used multiple chi-squared tests and ANOVA with Bonferroni correction.

A multivariate analysis of the use of images was carried out considering confounding factors such as age, sex, hypertension, overweight/obesity, diabetes, renal failure, heart failure, hospital stay, ICU stay, mechanical ventilation, and death. The calculated adjusted ORs show that there were no differences among the regions, and they do not appear to add significant variation or impact.

FINDINGS

The imaging findings and their regional distribution are shown in Table 3. The most frequent patterns of the cX-ray were peripheral, basal, and ground glass infiltrates with a significant prevalence of abnormalities in Mx. The ground glass appearance of peripheral or subpleural infiltrates on cCT was found in 89% of cases; the most severe subtypes (infiltrates >50%) were significantly higher in Mx (Figure 2). The left ventricular ejection fraction (LVEF) was calculated in all cEcho performed (266 patients) with a mean value of 57% being almost the same in the three regions.

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Chest computed tomography (cCT)	61.53% (883)	69.08% (181)	32.24% (138)	75.70% (564)	0.001
					0.001
					0.001
					0.036
Infiltrates in ground glass	89.35% (789/883)	99.45% (180/181)	87.68% (121/138)	86.52% (488/564)	0.001
					0.001
					0.719
					0.001
_____ % of pulmonary involvement					0.001
<25%	21.29%(168/789)	13.33% (24/180)	33.06% (40/121)	21.31% (104/488)	N/A
25–50%	32.95% (260/789)	18.33% (33/180)	41.32% (50/121)	36.27% (177/488)	
>50%	45.75% (361/789)	68.33% (123/180)	25.62% (31/121)	42.42% (207/488)	
Crazy Paving	30.01% (618/883)	20.99% (38/181)	45.65% (63/138)	29.08% (164/564)	0.001
					0.001
					0.001
					0.033
Alveolar Consolidation	36.58% (323/883)	35.36% (64/181)	42.75% (59/138)	35.46% (200/564)	0.261
					N/A
Pleural Effusion	10.76% (95/883)	12.71% (23/181)	18.84% (26/138)	8.16% (46/564)	0.001
					0.132
					0.001
					0.066
Chest X-Ray (cX-ray)	45.99% (660)	38.55% (101)	91.12% (390)	22.68% (169)	0.001
					0.001
					0.001
					0.001
Basal infiltrates	51.97% (343/660)	83.17% (84/101)	41.28% (161/390)	57.99% (98/169)	0.001
					0.001
					0.001
					0.001
Peripheral infiltrates	63.33% (418/660)	89.11% (90/101)	58.97% (230/390)	57.99% (98/169)	0.001
					0.001
					0.828
					0.001

Table 3 Image patterns, global and regional.

Notes: * Each cell contains four p-values.

The first p-value corresponds to chi-squared test (for categorical variables) or one-way ANOVA test (for numerical variables). Only a $p \leq 0.016$ was considered statistically significance.

The second, third, and fourth corresponds to multiple comparisons between groups: Mx and CAC, CAC and SAM, and SAM and Mx, respectively. We used multiple chi-squared tests and ANOVA with Bonferroni correction.

(Contd.)

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Hilar infiltrates	39.24% (259/660)	54.46% (55/101)	44.87% (175/390)	17.16% (29/169)	0.001 0.085 0.001 0.001
Ground glass pattern	45.00% (297/660)	74.26% (75/101)	43.59% (170/390)	30.77% (52/169)	0.001 0.001 0.004 0.004
Consolidation	25.15% (166/660)	57.43% (58/101)	19.23% (75/390)	19.53% (33/169)	0.001 0.001 0.935 0.001
Echocardiogram (cEcho)	18.54% (266)	24.43% (64)	18.93% (81)	16.24% (121)	0.013 0.085 0.241 0.003
Left ventricular ejection fraction (LVEF) (n = 266)	56.89 (SD 11.89)	57.40 (SD 9.78)	54.48 (SD 13.97)	58.23 (SD 11.22)	0.008 0.421 0.083 1.000
Right ventricular fractional area (FaRV) (n = 166)	38.17 (SD 10.61)	34.71 (SD 7.87)	30.33 (SD 6.80)	40.20 (SD 11.41)	0.002 1.000 0.311 0.004
Left ventricular global longitudinal strain (GLS LV) (n = 57)	-17.31 (SD 5.18)	-13 (SD 0)	-11.2 (SD 3.65)	-18.74 (SD 4.47)	0.001 1.000 0.001 0.591
Right ventricular free wall strain (FWSRV) (n = 18)	-24.85 (SD 6.85)	-15 (SD 0)	N/A	-25.42 (SD 6.60)	0.144
Transmitral pattern					0.001
<i>LV impaired relaxation</i>	41.73% (111/266)	68.75% (44/64)	30.86% (25/81)	34.71% (42/121)	N/A
<i>Atrial fibrillation</i>	7.89% (21/266)	3.12% (2/64)	4.94% (4/81)	12.40% (15/121)	
<i>Normal</i>	42.48% (113/266)	26.56% (17/64)	51.85% (42/81)	44.63% (54/121)	
<i>Restrictive pattern</i>	2.63% (7/266)	0.00% (0)	4.94% (4/81)	2.48% (3/121)	
<i>Pseudoformal pattern</i>	5.26% (14/266)	1.56% (1/64)	7.41% (6/81)	5.79% (7/121)	
Abnormal motility	15.79% (42/266)	9.38% (6/64)	25.93% (21/81)	12.40% (15/121)	0.010 0.011 0.014 0.538
Pericardial effusion	10.90% (29/266)	3.12% (2/64)	4.94% (4/81)	19.01% (23/121)	0.001 0.586 0.004 0.003

(Contd.)

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Lung ultrasound (LUS)	7.25% (104)	22.14% (58)	0.23% (1)	6.04% (45)	0.001 0.001 0.001 0.001
Interstitial syndrome	55.77% (58/104)	96.55% (56/58)	100.00% (1/1)	2.22% (1/45)	0.001 0.850 0.001 0.001
Consolidation	10.57% (11/104)	18.96% (11/58)	0.00% (0)	0.00% (0)	0.426 N/A
Pleural effusion	9.62% (10/104)	5.17% (3/58)	0.00% (0)	15.56% (7/45)	0.197 N/A




Figure 2 Image patterns. **(A)** cTC: infiltrates in ground glass >50%, crazy paving and alveolar consolidation bilateral; **(B)** cTC: infiltrates in ground glass >50% bilateral; **(C)** cTC: infiltrates in ground glass 25–50% and pleural effusion bilateral; **(D)** cTC: infiltrates in ground glass <25% and pleural effusion unilateral; **(E)** cX-ray: peripheral, basal, and hilar infiltrates; ground glass pattern; and consolidation; **(F)** cX-ray: basal and peripheral infiltrates, and ground glass pattern.




Figure 3 Left ventricle and right ventricle echocardiographic systolic analysis.

The right ventricular fractional area (FaRV) was performed in almost 62% of the cEcho (166 patients) with a mean value of 38% and no differences between regions. Strain echocardiography was performed only in Mx and SAM. The left ventricular global longitudinal strain (GLSLV) was performed in 21% of cEcho (57 patients) with a median of -17 (from -26 to -7) and lower in Mx (-13). The right ventricular free wall strain (FWSRV) was achieved in 7% of cEcho (18 patients) with a median value of -25 (from -40 to -7); it was also lower in Mx

(-15) (Figure 3). The transmitral/tissue Doppler patterns most frequently were majority normal or impaired relaxation (42% each). The development of abnormal regional wall motility was predominant in CAC. Pericardial effusion was found in 11% of the patients, with the majority in SAm. The most frequent patterns in LUS were the interstitial syndrome (predominant in Mx and CAC) and consolidation (predominant in Mx). Logistic regression showed associations of imaging with comorbidities, complications, and evolution with an estimation of crude OR and their 95%CI.

The most frequently finding in ECG was an arrhythmia, especially in SAm.

ASSOCIATED FACTORS RELATED TO PATHOLOGICAL FINDINGS IN IMAGES

On cX-ray, peripheral infiltrates were associated with mechanical ventilation (OR 1.66; 95%CI 1.19–2.32), mortality (OR 1.87; 95%CI 1.30–2.70) and overweight/obesity (OR 2.93; 95%CI 2.10–4.08). Meanwhile basal infiltrates were associated with mechanical ventilation (OR 2.84; 95%CI 2.05–3.94), mortality (OR 2.84; 95%CI 1.99–4.06), heart failure (OR 2.06; 95%CI 1.35–3.14), and overweight/obesity (OR 1.75; 95%CI 1.27–2.41).

On cCT, ground glass infiltrates >50% were associated with mechanical ventilation (OR 4.99; 95%CI 3.66–6.81), mortality (OR 3.68; 95%CI 2.63–5.15), heart failure (OR 2.75; 95%CI 1.73–4.36), and overweight/obesity (OR 1.84; 95%CI 1.36–2.49).

Regarding echocardiograms, the abnormal LVEF was associated with ischemic heart disease (OR 15.64; 95%CI 6.77–36.14) and the presence of heart failure (OR 7.26; 95%CI 3.73–14.16).

On LUS, interstitial syndrome resulted associated with mortality (OR 2.64; 95% 1.14–6.09).

OTHER ANALYSES

Renal failure (20%) was the most prevalent complication, with a significant predominance in Mx and SAm regions. Heart failure developed in 13% (191 patients) of the cohort, with a predominance in Mx and CAC; left ventricular failure occurred in 46%, right ventricular failure occurred in 20%, and biventricular failure occurred in 34% of cases. Lung thromboembolism was significantly higher in Mx, and acute myocardial infarction was predominant in CAC (Table 4).

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Complications					
Renal failure	20.14% (289)	22.52% (59)	13.32% (57)	23.22% (173)	0.001 0.002 0.001 0.816
Heart failure	13.13% (191)	16.79% (44)	19.86% (85)	8.32% (62)	0.001
RV	20.41% (39/191)				0.316
LV	45.54% (87/191)				0.001
RV + LV	34.05% (65/191)				0.001
Cardiac arrest	4.81% (69)	0.76% (2)	9.58% (41)	3.49% (26)	0.001 0.001 0.001 0.021
Myocardial infarction	4.04% (58)	2.29% (6)	7.94% (34)	2.42% (18)	0.001 0.002 0.001 0.908

Table 4 Complications and evolution.

Notes: * Each cell contains four p-values.

The first p-value corresponds to chi-squared test (for categorical variables) or one-way ANOVA test (for numerical variables). Only a $p \leq 0.016$ was considered statistically significance.

The second, third, and fourth corresponds to multiple comparisons between groups: Mx and CAC, CAC and SAm, and SAm and Mx, respectively. We used multiple chi-squared tests and ANOVA with Bonferroni correction.

RV: right ventricular; LV: left ventricular; ICU: intensive care unit; prone: pronation; CPAP: continuous positive airway pressure; ECMO: extracorporeal membrane oxygenation.

(Contd.)

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Myocarditis	3.41% (49)	3.44% (9)	7.71% (33)	0.94% (7)	0.001 0.023 0.001 0.005
Lung thromboembolism	3.34% (48)	10.69% (28)	1.40% (6)	1.88% (14)	0.001 0.001 0.543 0.001
Deep venous thrombosis	0.56% (8)	0.38% (1)	0.70% (3)	0.54% (4)	0.856 N/A
Takotsubo	0.21% (3)	0.38% (1)	0.23% (1)	0.13% (1)	0.746 N/A
Evolution					
Ward admission	49.34% (708)	61.07% (160)	47.90 (205)	46.04% (343)	0.001 0.001 0.539 0.001
ICU admission	50.66% (727)	38.93% (102)	52.10% (223)	53.96% (402)	0.001 0.001 0.539 0.001
ICU during hospitalization	58.26% (836)	60.69% (159)	57.48% (246)	57.85% (431)	0.672 N/A
Hospitalization days	17.49 (SD 17.24)	16.01 (SD 261)	15.39 (SD16.04)	19.21 (SD 19.02)	0.001 1.000 0.001 0.028
ICU days	13.56 (SD 14.2)	13.35 (SD12.68)	7.94 (SD 8.36)	16.73 (SD 16.09)	0.001 0.003 0.001 0.079
Mechanical ventilation, total patients	37.91% (544)	51.53% (135)	29.91% (128)	37.72% (281)	0.001 0.001 0.007 0.001
Mechanical ventilation, ICU patients	65.07% (544/836)	84.91% (135/159)	52.03% (128/246)	65.20% (281/431)	0.001 0.001 0.001 0.001
Mechanical ventilation duration (hours)	356.61 (SD 298.12)	308.26 (SD 271.15)	241.89 (SD 198.75)	432.11 (SD 326.17)	0.001 0.185 0.001 0.001
Mechanical ventilation duration (days)	14.85 (SD 12.42)	12.84 (SD 11.29)	10.07 (SD 8.28)	18.01 (SD 13.59)	0.001 0.185 0.001 0.001

(Contd.)

	GLOBAL (n = 1,435)	MEXICO (MX) (n = 262)	CENTRAL AMERICA AND CARIBBEAN (CAC) (n = 428)	SOUTH AMERICA (SAM) (n = 745)	p-VALUE*
Prone / total patients	22.37% (321)	41.98% (110)	7.24% (31)	24.16% (180)	0.001 0.001 0.007 0.001
Prone, ICU patients	37.80% (316/836)	67.30% (107/159)	11.79% (29/246)	41.76% (180/431)	0.001 0.001 0.001 0.001
Prone, mechanical ventilation	50.18% (273/544)	72.59% (98/135)	18.75% (24/128)	53.74% (151/281)	0.001 0.001 0.001 0.001
Prone duration (hours)	137.09 (SD 94.74)	141.6 (SD 91.19)	61.93 (SD 56.71)	147.28 (SD 96.68)	0.004 0.001 0.001 1.000
CPAP, total patients	13.17% (189)	12.21% (32)	10.28% (44)	15.17% (113)	0.051 N/A
CPAP, mechanical ventilation	17.83% (97/544)	9.63% (13/135)	13.28% (17/128)	23.84% (67/281)	0.001
CPAP duration (hours)	120.42 (SD 120.63)	98.25 (SD 93.32)	83.45 (SD 96.48)	141.10 (SD 131.65)	0.012 1.000 0.020 0.218
Nasal cannula	49.69% (713)	66.41% (174)	49.07% (210)	44.16% (329)	0.001 0.001 0.105 0.001
Nasal cannula duration (hours)	150.90 (SD 149.49)	214.20 (SD 161.48)	80.11 (SD 76.38)	162.60 (SD 159.90)	0.001 0.001 0.001 0.001
ECMO	0.56% (8)	0.38% (1)	0.00% (0)	0.94% (7)	0.105 N/A
ECMO (hours)	237 (SD 208.61)	504 (SD N/A)	–	198.85 (SD 192.85)	0.189 N/A
Mortality/total patients	27.60% (396)	37.40% (98)	24.07% (103)	26.17% (195)	0.001 0.001 0.424 0.001
Mortality/mechanical ventilation	56.07% (305/544)	57.78% (78/135)	59.38% (76/128)	53.74% (151/281)	0.510 N/A
Mortality/ICU patients	39.83% (333/836)	52.20% (83/159)	36.18% (89/246)	37.35% (161/431)	0.002 0.001 0.760 0.001

Modalities of respiratory support had significant differences across regions: Overall, mechanical ventilation (MV) and pronation predominated in Mx ICU patients at 85% and 67%, respectively, although the mechanical ventilation duration (hours and days) was higher in SAm. CPAP in mechanical ventilated patients was more common in SAm; ECMO was rarely employed (Table 4).

The overall in-hospital mortality was 28% (95%CI: 25.2–29.9) and was significantly higher in those aged ≥ 65 years with no differences between gender; this is nearly similar to that published in patients from the United Kingdom [19] and slightly higher than that of Iran [20]. The higher regional mortality was in Mx (37%) with no significant differences between CAC and SAm. Rather, if we analyze for each country, then Perú and Argentina had the highest mortality with 40% and 39%, respectively. The ICU mortality was 40% and was significantly higher in México (52%). Mortality in patients with mechanical ventilation was 56% with no differences between regions (Table 4). The risk factors associated with high mortality were HBP, DBT, and overweight/obesity, as well as hospitalization location and the requirement of MV.

DISCUSSION

KEY RESULTS/INTERPRETATION

The SARS-CoV-2 pandemic has had a global influence, but little is known about the effect on LATAM. The respiratory system is dramatically impacted by COVID-19, and this explains the necessary use of cX-ray and cCT overshadowing the use of cEcho and LUS. In this multicenter study, we describe the different modalities of imaging used and their findings in the management of patients affected during the early stages of the COVID-19 disease in LATAM. The three regions had expected as well as unexpected results.

The diagnosis and follow-up of pulmonary involvement was carried out using lung imaging (cX-ray or cCT). The procedures optimized the technical and human resources available in light of the personnel protection measures. Only in doubtful or complex cases were both techniques used in the same patient (18%). This could partly explain the difference in the use of these modalities between the three regions. The findings of basal and peripheral infiltrates on cX-ray and of ground glass infiltrates (>50%) in cCT were correlated with the presence of overweight/obesity, greater occurrence of heart failure, need for mechanical ventilation, and higher mortality.

According to SISIAC's recommendations, the use of cEcho during the COVID-19 pandemic in 2020 was limited to patients with hemodynamic instability, new heart failure or ischemic heart disease, complex arrhythmias, or a high suspicion of endocarditis associated with coronavirus. The higher prevalence of heart failure, myocardial infarction, and pulmonary thromboembolism in Mx and CAC could probably explain the slightly higher use of cEcho in these regions. The development of a reduced ejection fraction during hospitalization was correlated with the presence of heart failure and ischemic heart disease.

Uncertainties about its usefulness and the lack of practice of LUS in patients with pulmonary and cardiac pathology in most LATAM countries contributed to the limit use of this technique except in Mexico and Brazil. Of note, published studies [21] that used LUS in COVID-19 patients were oriented to usefulness and results, and it remains unclear what the real rate of LUS use was. Interstitial infiltrates were correlated with higher mortality.

REGARDING REGIONS

We hypothesize that the higher mortality in Mx could be explained by a combination of these findings: a higher prevalence of cX-ray infiltrates; cCT infiltrates >50% in more than two-thirds of the subjects; high incidence of interstitial syndrome in LUS; highest ICU stay in days; highest proportion of total patients admitted to the ICU with mechanical ventilation and pronation use (more severe ICU patients); and a higher prevalence of pulmonary thromboembolism, heart failure, and renal failure. Furthermore, the high incidence of comorbidities such as obesity, diabetes, and tobacco use suggest a high-risk cohort.

The CAC and SAm regions had fewer numbers of complications; there was less prevalence of abnormal cX-ray findings and a higher rate of moderate cCT infiltrates (25–50%). These regions had a lower proportion of total patients admitted to the ICU with mechanical ventilation and pronation use (less severe ICU patients); these could probably identify a moderate risk cohort. Interestingly, we found that the CAC region had the highest rate of hypertension and the

highest proportion of regional wall motion abnormalities on cEcho, and SAM had the highest rate of arrhythmias as well as the highest prevalence of pericardial effusions. We hypothesize that the combination of these factors could probably explain the similar mortality between both regions (24% and 26%, respectively).

LIMITATIONS/GENERALIZABILITY

The cohort might not be representative of all COVID-19 hospitalizations in each country because we included only patients who had some imaging performed.

Modality of choice of the images used in each patient was based on the treating physician, with considerable risk of confounding by indication: patients had certain modalities based on clinical presentation, availability of diagnostic images, and local guidelines in place for imaging. So the generalizability of the findings is limited to hospitalized COVID patients within Latin America.

Another limitation to mention is that each center had its own imaging protocols and reports, although we collected all images in a core lab and standardized its interpretation for the final analysis.

We could also consider an underreporting of ECG due to a lack of digitization.

In addition, data were collected during the first pandemic wave, and therefore findings may not reflect changes that may have occurred later.

CONCLUSION

Patients hospitalized with COVID-19 had differences in the images used in the three LATAM regions. These could be explained by clinical needs, personnel protection measures, and/or hospitalization location. cCT and cX-ray were the most frequently performed modalities, and cEcho was employed only in special clinical situations.

The cardiopulmonary images used and their abnormal findings had a great impact on diagnosis and prognosis, the use of mechanical ventilation, the necessary pronation, and overall mortality. The addition of comorbidities and complications could explain the different severity rates in these patients.

ABBREVIATIONS

BMI: Body Mass Index

CAC: Central America and Caribbean region

cCT: chest computed tomography

cEcho: echocardiogram

cMRI: cardiac magnetic resonance imaging

COPD: chronic obstructive pulmonary disease

cX-ray: chest X-ray

DBT: diabetes

ECG: electrocardiogram

FaRV: right ventricular fractional area

FWSRV: right ventricular free wall strain

GLSLV: left ventricular global longitudinal strain

HBP: high blood pressure

ICU: intensive care unit

IRB: Institutional Review Board

ISR: imaging services resources

LATAM: Latin America

LUS: lung ultrasound

LVEF: left ventricular ejection fraction

MV: mechanical ventilation

Mx: Mexican region

SAm: South America region

FUNDING INFORMATION

RIMAC was designed and conducted by Society of Cardiovascular Images of the Inter-American Society of Cardiology (SISIAC). SISIAC is a nonprofit academic-scientific entity that involves 23 countries throughout the Americas. It was founded in 2004 with the initial name of ECOSIAC.

This study is not sponsored by any public or private entity, nor will it have any remuneration or charge for the researchers who participate in it.

STRENGTHS

To the best of our knowledge, this is the first international, multicenter study in LATAM to characterize cardiopulmonary imaging use and their findings in patients hospitalized with COVID-19.

FUTURE DIRECTIONS

Subsequently, imaging societies may consider developing risk scoring protocols based on the findings of the images performed.

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHOR AFFILIATIONS

Salvador V. Spina, MD  orcid.org/0000-0002-4884-0223

Hospital Aeronáutico Central, Buenos Aires, AR

Marcelo L. Campos Vieira, MD  orcid.org/0000-0002-4561-5717

Hospital Israelita Albert Einstein, São Paulo, BR

César J. Herrera, MD  orcid.org/0000-0002-3546-5225

CEDIMAT, Santo Domingo, DO

Ana G. Munera Echeverri, MD  orcid.org/0000-0003-3541-4652

Hospital General de Medellín, Medellín, CO

Pamela Rojo, MD  orcid.org/0000-0001-6373-5694

Clínica Dávila, Santiago de Chile, CL

Alma S. Arrijo Salazar, MD  orcid.org/0000-0002-3341-9241

Clínica Dávila, Santiago de Chile, CL

Zuilma Y. Vázquez Ortiz, MD  orcid.org/0000-0001-5956-7333

Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Ciudad de México, MX

Roberto Baltodano Arellano, MD  orcid.org/0000-0002-7538-2125

HNG Almenara Irigoyen, Lima, PE

Graciela Reyes, MD  orcid.org/0000-0002-9778-9858

Hospital El Cruce, Provincia Buenos Aires, AR

Rocío Aceves Millán, MD  orcid.org/0000-0001-8982-111X

Centro Médico Nacional 20 de Noviembre, Ciudad de México, MX

Juan A. Calderón González, MD  orcid.org/0000-0002-5171-9635

Hospital General de Zona Número 4, Monterrey, MX

Ana C. Camarozano, MD  orcid.org/0000-0002-9291-1308

Hospital Nossa Senhora das Graças y Universidade Federal do Paraná, BR

Edgar Avilés, MD  orcid.org/0000-0002-4283-6151

Complejo Hospitalario Dr. Arnulfo Arias Madrid, Ciudad de Panamá, PA


- Marco A. Cabrera, MD**  orcid.org/0000-0002-4497-9084
TECNISCAN Hospitalia, Ciudad de Guatemala, GT
- María F. Grande Ratti, PhD**  orcid.org/0000-0001-8622-8230
Internal Medicine Research Area, Hospital Italiano de Buenos Aires, AR
- Jorge Lowenstein, MD**  orcid.org/0000-0001-5804-9075
Instituto de Investigaciones Médicas, Buenos Aires, AR
- Rodrigo Hernández Vyhmeister, MD**  orcid.org/0000-0002-3722-4871
Hospital de la Fuerza Aerea, Santiago de Chile, CL
- Pamela Piña Santana, MD**  orcid.org/0000-0002-5404-4389
CEDIMAT, Santo Domingo, DO
- Jaime A. Ibarra Burgos, MD**  orcid.org/0000-0002-3928-9310
Medicina Interna Universidad CES, Medellín, CO
- Alejandra Rivera, LPN**  orcid.org/0000-0003-1412-5026
Clínica Dávila, Santiago de Chile, CL
- Beatriz A. Fernández Campos, MD**  orcid.org/0000-0001-8030-4239
Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Ciudad de México, MX
- Kelly M. Cupe Chacalcaje, MD**  orcid.org/0000-0002-7497-3898
HNG Almenara Irigoyen, Lima, PE
- Mariela De Santos, MD**  orcid.org/0000-0002-7335-2037
Hospital El Cruce, Provincia Buenos Aires, AR
- Tania R. Afonso, LPN**  orcid.org/0000-0002-3673-6605
Hospital Israelita Albert Einstein, São Paulo, BR
- Tomás Miranda Aquino, MD**  orcid.org/0000-0002-4967-8969
Centro Médico Nacional 20 de Noviembre, Ciudad de México, MX
- Ana L. Lalyre Acosta, MD**  orcid.org/0000-0002-9445-7014
Complejo Hospitalario Dr. Arnulfo Arias Madrid, Ciudad de Panamá, PA
- Beatriz Domínguez, MD**  orcid.org/0000-0003-0771-1211
TECNISCAN Hospitalia, Ciudad de Guatemala, GT
- Federico Campos, MD**  orcid.org/0000-0002-8051-5332
CEDIMAT, Santo Domingo, DO
- Sergio M. Alday Ramírez, MD**  orcid.org/0000-0002-0878-508X
Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Ciudad de México, MX
- Angela V. Cachicatari Beltran, MD**  orcid.org/0000-0001-7908-5200
HNG Almenara Irigoyen, Lima, PE
- Daniela Alvarez, MD**  orcid.org/0000-0003-4109-6216
Hospital El Cruce, Provincia Buenos Aires, AR
- Patricia de Oliveira Roveri, MD**  orcid.org/0000-0001-9037-4716
Hospital Israelita Albert Einstein, São Paulo, BR
- Carlos Rosales Ixcamparij, MD**  orcid.org/0000-0001-9078-220X
Centro Médico Nacional 20 de Noviembre, Ciudad de México, MX
- Ender Otoniel González, MD**  orcid.org/0000-0002-1473-1408
TECNISCAN Hospitalia, Ciudad de Guatemala, GT
- Pedro Vargas, MD**  orcid.org/0000-0002-2114-6856
CEDIMAT, Santo Domingo, DO
- Maximiliano Flores Flamand, MD**  orcid.org/0000-0002-8530-696X
Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Ciudad de México, MX
- Rosa L. López Martínez, MD**  orcid.org/0000-0002-1307-870X
HNG Almenara Irigoyen, Lima, PE
- Luciana Meza**  orcid.org/0000-0001-5956-7333
Technique, Hospital El Cruce, Provincia Buenos Aires, AR
- Samira Saady Morthy, MD**  orcid.org/0000-0002-5531-9647
Hospital Israelita Albert Einstein, São Pablo, BR
- Rudy Ovalle**  orcid.org/0000-0003-4021-1470
Technique, TECNISCAN Hospitalia, Ciudad de Guatemala, GT
- Stalin Martínez, MD**  orcid.org/0000-0002-8664-3044
CEDIMAT, Santo Domingo, DO
- Oscar A. Pérez Orpinel, MD**  orcid.org/0000-0001-6599-6716
Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Ciudad de México, MX
- Mauricio Potito, MD**  orcid.org/0000-0003-2429-5141
Hospital El Cruce, Provincia Buenos Aires, AR
- María Verónica Espinoza Arregui, MD**  orcid.org/0000-0002-4950-7000
TECNISCAN Hospitalia, Ciudad de Guatemala, GT

Jorge Marte Baez, MD  orcid.org/0000-0002-6729-7027
CEDIMAT, Santo Domingo, DO

Consuelo Orihuela Sandoval, MD  orcid.org/0000-0003-2334-9769
Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Ciudad de México, MX

Marcos Granillo Fernandez, MD  orcid.org/0000-0001-7379-1833
Hospital El Cruce, Provincia Buenos Aires, AR

Rohit Loomba, MD  orcid.org/0000-0002-9116-2835
Advocate Children’s Hospital/Rosalind Franklin University of Medicine and Science, Chicago, IL, US

Saúl Flores, MD  orcid.org/0000-0002-6274-5775
Texas Children’s Hospital/Baylor School of Medicine, Houston, TX, US

José M. Hernández, MD  orcid.org/0000-0002-4018-7346
Cardiolink Estudios Cardiovasculares, Monterrey, MX

Ricardo Pignatelli, MD  orcid.org/0000-0002-3862-7672
Children’s Hospital, Baylor College of Medicine, Houston, US

REFERENCES

1. **Peng Z, Xing-Lou Y, Xian-Guang W**, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020; 579(7798): 270–273. DOI: <https://doi.org/10.1038/s41586-020-2012-7>
2. **Nanshan C, Min Z, Xuan D**, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet*. 2020; 395(10223): 507–513. DOI: [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
3. **Chaolin H, Yeming W, Xingwang L**, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020; 395(10223): 497–506. DOI: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
4. **Wu Z, McGoogan JM**. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020; 323(13): 1239–1242. DOI: <https://doi.org/10.1001/jama.2020.2648>
5. **Fang L, Karakiulakis G, Roth M**. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med*. 2020; 8(4): e21. DOI: [https://doi.org/10.1016/S2213-2600\(20\)30116-8](https://doi.org/10.1016/S2213-2600(20)30116-8)
6. **Richardson S, Hirsch JS, Narasimhan M**, et al. Presenting characteristics, comorbidities, and outcomes among 5,700 patients hospitalized with COVID-19 in the New York City area. *JAMA*. 2020; 323(20): 2052–2059. DOI: <https://doi.org/10.1001/jama.2020.6775>
7. **Wang D, Hu B, Hu C**, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020; 323(11): 1061–1069. DOI: <https://doi.org/10.1001/jama.2020.1585>
8. **Mehraeen E, Seyed Alinaghi SA, Nowroozi A**, et al. A systematic review of ECG findings in patients with COVID-19. *Indian Heart Journal*. 2020; 72(6): 500–507. DOI: <https://doi.org/10.1016/j.ihj.2020.11.007>
9. **Moussa S, Gabriels J, Chang D**, et al. Effects of chloroquine, hydroxychloroquine, and azithromycin on QTc of COVID-19 patients. *Circulation Arrhythmia and Electrophysiology*. 2020; 13(6): 496–504. DOI: <https://doi.org/10.1161/CIRCEP.120.008662>
10. **Ming-Yen N, Elaine YPL, Jin Y**, et al. Imaging profile of the COVID-19 infection: Radiologic findings and literature review. *Radiology Cardiothoracic Imaging*. 2020; 2(1): 1–9. DOI: <https://doi.org/10.1148/ryct.2020200034>
11. **Kirkpatrick JN, Mitchell C, Taub C**, et al. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak: Endorsed by the American College of Cardiology. *Journal American Society of Echocardiography*. 2020; 33(6): 648–653. DOI: <https://doi.org/10.1016/j.echo.2020.04.001>
12. **Szekely Y, Lichter Y, Taieb P**, et al. The spectrum of cardiac manifestations in coronavirus disease 2019 (COVID-19)—A systematic echocardiographic study. *Circulation*. 2020; 142(4): 342–353. DOI: <https://doi.org/10.1161/CIRCULATIONAHA.120.047971>
13. **García Fernández MA**. La pandemia Covid19 y el uso de la ecocardiografía. *RETIC* 2020; 3(2): 1–4. DOI: <https://doi.org/10.37615/retic.v3n2a2>
14. **Li Y, Li H, Zhu S**, et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. *JACC: Cardiovascular Imaging*. 2020; 13(11): 2287–2299. DOI: <https://doi.org/10.1016/j.jcmg.2020.04.014>
15. **Hirschaut E, Delgado C**. Ecografía pulmonar: Un nuevo abordaje para cardiólogos. *RETIC*. 2018; 1(2): 1–7. DOI: <https://doi.org/10.37615/retic.v1n2a2>
16. **Poggiali E, Dacrema A, Bastoni D**, et al. Can lung US help critical care clinicians in the early diagnosis of novel coronavirus (COVID-19) pneumonia? *Radiology*. 2020; 295(3): e6. DOI: <https://doi.org/10.1148/radiol.2020200847>

17. **Feng P, Chuansheng Z, Tianhe Y**, et al. Different computed tomography patterns of coronavirus disease 2019 (COVID-19) between survivors and non-survivors. *Scientific Reports*. 2020; 10(1): 11336. DOI: <https://doi.org/10.1038/s41598-020-68057-4>
18. **Long C, Xu H, Shen Q**, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? *European Journal of Radiology*. 2020; 126: 108961. DOI: <https://doi.org/10.1016/j.ejrad.2020.108961>
19. **Docherty AB, Harrison EM, Green CA**, et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterization Protocol: Prospective observational cohort study. *BMJ*. 2020; 369: m1985. DOI: <https://doi.org/10.1136/bmj.m1985>
20. **Jalili M, Payandemehr P, Saghaei A**, et al. Characteristics and mortality of hospitalized patients with COVID-19 in Iran: A national retrospective cohort study. *Ann Intern Med*. 2021; 174(1): 125–127. DOI: <https://doi.org/10.7326/M20-2911>
21. **Volpicelli G, Gargani L, Perlini S**, et al. Lung ultrasound for the early diagnosis of COVID-19 pneumonia: An international multicenter study. *Intensive Care Med*. 2021; 47(4): 444–454. DOI: <https://doi.org/10.1007/s00134-021-06373-7>

TO CITE THIS ARTICLE:

Spina SV, Campos Vieira ML, Herrera CJ, Múnera Echeverri AG, Rojo P, Arrijoja Salazar AS, Vázquez Ortiz ZY, Arellano RB, Reyes G, Millán RA, Calderón González JA, Camarozano AC, Avilés E, Cabrera MA, Grande Ratti MF, Lowenstein J, Vyhmeister RH, Santana PP, Ibarra Burgos JA, Rivera A, Fernández Campos BA, Cupe Chacalcaje KM, De Santos M, Afonso TR, Aquino TM, Lalyre Acosta AL, Domínguez B, Campos F, Alday Ramirez SM, Cachicatari Beltran AV, Alvarez D, de Oliveira Roveri P, Ixcamparij CR, González EO, Vargas P, Flamand MF, López Martínez RL, Meza L, Morthy SS, Ovalle R, Martínez S, Pérez Orpinel OA, Potito M, Espinoza Arregui MV, Baez JM, Sandoval CO, Fernández MG, Loomba R, Flores S, Hernández JM, Pignatelli R. Cardiopulmonary Imaging Utilization and Findings among Hospitalized COVID-19 Patients in Latin America. *Global Heart*. 2022; 17(1): 49. DOI: <https://doi.org/10.5334/gh.1134>

Submitted: 10 January 2022

Accepted: 30 May 2022

Published: 01 August 2022

COPYRIGHT:

© 2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See <http://creativecommons.org/licenses/by/4.0/>.

Global Heart is a peer-reviewed open access journal published by Ubiquity Press.